SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.
BörsenkürzelSGP
Name des UnternehmensSpyGlass Pharma Inc
IPO-datumFeb 06, 2026
CEO- -
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
Geschäftsjahresende- -
Addresse27081 Aliso Creek Road
Stadt
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92656
Telefon
Website
BörsenkürzelSGP
IPO-datumFeb 06, 2026
CEO- -
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten